IHS IM 20201006C OV I D T E S T I N G
AT T H E S P E E D
O F L I G H T
The World’s Fastest Non-invasive Covid Test Harnessing the power of Mass Spectrometry and Artificial Intelligence to deliver test results at the speed of light.
Using a mouthwash or nasopharyngeal swab SpectraLIT delivers safe, reliable, low cost
point of care testing with results in 20 seconds.
Vaccines are only part of the solution to eliminating COVID as they are designed to prevent serious illness, but recipients can still spread and contract the virus. Testing will continue to play a vital role in maintaining the health of the global population and economies.
Inventive Health has agreed to merge with Virusight, a joint venture of two of Israel's leading medical innovators – Sheba Medical Centre and Newsight Imaging - to market SpectraLIT , anaffordable,rapid point-of-care pathogen testing solution that delivers on-site analysis and resultswithin 20 seconds.
Combining the power of mass spectrometry and Artificial Intelligence, the CE Approved SpectraLIT performs high resolution spectral profiling of substances and through Machine Learning can be trained to detect any variant or pathogen.
Samples are collected via nasopharyngeal swab or non-invasive mouthwash making it safe for frequent use by adults and children by avoiding the risk of trauma caused by repeated nasal swabbing.
Measuring only 100mm x 65mm x 77mm the portable SpectraLIT device can be easily scaled and quickly deployed to fit into any point of care environment including transport hubs, stadiums, entertainment venues, cruise ships, doctors’ surgeries, pharmacies, schools, universities, offices, hospitals and aged care facilities.
Being digital and IOT enabled the SpectraLIT solution can integrate with track and trace and other eHealth systems.
The business will derive revenue from sales of the device as well as each test.
Inventive Health executives have a proven track record in building businesses in Healthcare and Information Technology. These executives will have management control under the merger. Offices are established in Sydney, Australia, Tel Aviv, Israel and London, UK with plans to expand across Europe and the Americas.
Inventive Health and Virusight have agreedto mergewith Virusightbeing the new operating companyand with Inventive having an 18% stake. The new entity will have a post money valuation in excess of US$90m.
Executive Summary
Three Pillars to Recovery A cornerstone of containing the COVID-19 pandemic is widespread testing to identify cases and prevent new outbreaks emerging.
Source: Doherty Institute, Victoria, Australia
Vaccination Social Distancing
SpectraLIT™ - Unique Approach to Testing
Combining the power of mass spectrometry and Artificial Intelligence, SpectraLIT™ is a portable, non-invasive pathogens diagnostic device that can: Be trained to detect any virus including SARS-CoV-2 and its variants using
Supervised Machine Learning
Provide rapid results within 20 seconds
Use either non-invasive mouthwash sample or nasopharyngeal swab
Fit in the palm of your hand making it easy to set up at any point of care
Low cost to administer and test using readily available saline and cuvettes with no expensive consumables, chemicals or staffing requirements
Competitor Landscape
The COVID-19 testing landscape is complex, with multiple providers offering solutions for every budget and scenario.
To understand the landscape and Inventive Health's position within it, we have plotted key competitors against measures for cost and the delivery time of a result.
It should be noted that a number of these products are in concept / prototype phase.
Time
O C
T O
B E
R 2
0 2
0
Available Testing Technologies PCR Testing (Swab Test) Polymerase chain reaction (PCR) testing is currently the most common form of testing globally and is seen as the gold standard. Lighthouse Labs, which are dedicated to COVID-19 testing, found PCR tests are around 99% effective. These types of tests have been used by the NHS in their testing centres around the country for the past few months and are the tests sent out by the NHS to people who have symptoms. For PCR tests, a swab is used to collect an RNA sample (the nucleic acid that converts DNA into proteins) from the patient's tonsils and inside their nose. RNA is collected as it carries the genetic information of this specific virus. This is then sent to a laboratory where the sample is heated and cooled so it multiplies into larger quantities of DNA. Bio-scientists can then see whether the SARS-CoV- 2 virus (the virus that causes COVID-19) is present. Because of the process, PCR test results take about two days and are the most expensive to administer.
LAMP Test Loop-mediated Isothermal Amplification (LAMP) is a similar process to PCR testing but produces many more viral RNA copies at a constant temperature instead of heating and cooling so can have a result much quicker - within a couple of hours or even faster. A swab is used to take samples from the nose or throat, or mucus from hard coughing can also be used. The swabbing does not need to be as vigorous as it is for the PCR test. The samples are then placed in vials of reagents (substances that produce a chemical reaction to detect the RNA), then heated in a special machine for 20 minutes. The machine then analyses the sample and confirms if there is any SARS-CoV-2 RNA. LAMP technology has been used to test NHS staff in Liverpool as part of a pilot in the city to "inform a blueprint for how mass testing can be achieved and how fast and reliable COVID-19 testing can be delivered at scale", the UK Department of Health and Social Care said.
Fast PCR Test Machines that can deliver on-the-spot genetic testing are being used to collect RNA for PCR testing, which can also detect the common flu. The RNA, taken using swab samples placed into a cartridge, is inserted into the machine which carries out a PCR test and then identifies if the virus is present within 30 – 90 minutes. A successful pilot test across eight London hospitals using British start-up DnaNudge's machines is being rolled out to urgent NHS patient care and elective surgery settings UK-wide, plus out of hospital settings, with the plan to deliver 5.8 million tests.
Antibody Test Antibody testing looks at whether your body has produced any antibodies to fight against the virus. A blood test is taken from a person who has had COVID-19 symptoms that have disappeared three to four weeks before. A lab test then takes a unique protein the virus makes and tests whether any antibodies in the blood bind to that protein. There are pin-prick tests in development which would allow a person to submit their own blood test, but these have not been rolled out yet. Unlike other diseases, the UK government and the World Health Organisation agree there is currently no evidence that someone with antibodies will not catch COVID-19 again in the future. A study by Imperial College found the levels of protective antibodies in people who have had COVID-19 drop "quite rapidly". Another study found T-cells, which attack the infected cells, were lasting longer than antibodies - six months after infection.
No Swab Saliva Test Patients can do this test at home by collecting about two millimetres of saliva into a sample pot, then sending it off to a laboratory. The sample gets tested using LAMP technology in a lab and the result is then texted to the person. It still takes about 48 hours but there is no need for a patient to leave their home or stick a swab down their throat or up their nose. A government-funded trial in Southampton was expanded from GPs to the city's university staff and students, and four schools.
Antigen Test These tests look for antigens - proteins that are produced by the body when it recognises a foreign structure, such as the COVID-19 virus. Antigens can easily be detected in saliva and laboratory testing is not necessary, so can be done in places such as care homes and without a medical professional. Results can be provided more quickly than PCR tests, with some systems already available and dozens more being developed.
Lateral Flow Test These tests are designed to identify asymptomatic people and have been used across the UK as part of the mass testing plan. It uses similar technology to a pregnancy test. A swab is inserted into the nose or throat, then the sample is inserted into a tube of liquid for a short time which extracts the molecule that determines if COVID-19 is present. No laboratory equipment is needed as a few drops of liquid are then dropped onto a small strip. Within 15 minutes, the strip of paper will show up with two lines if it is positive, one line on the top if it is negative or one line on the bottom if the test is invalid. While the test result returns relatively quickly, there are questions over its sensitivity, with the FDA now warning the US market to stop using the widely used Innova SARS-CoV-2 Antigen Rapid Qualitative Test for diagnostic use over significant concerns that the performance of the test has not been adequately established, presenting a risk to health through false negative and false positive results.
20 Second Test Announced in September 2020, the Virolens system uses a portable machine which creates a microscopic holographic image to detect the virus in saliva samples in 20 seconds. Developed by British companies iAbra and TT Electronics, it uses a digital camera attached to a microscope, which then runs data through a computer that can identify the virus from other cells. The device has been trialled at Heathrow Airport, whose chief executive, John Holland-Kaye, has urged the government to fast-track the technology to be used across the UK.
Either Oral/Nasal swab or mouth wash samples will be
taken from the patient.
The sample will be inserted into the SpectraLIT™.
After connecting the SpectraLIT™ to the PC/mobile the operator runs the test using the App. Data is captured which can be used to integrate with test and
trace systems.
Test Process Supported by both swab and mouthwash test
If the virus is detected the same sample can be dispatched to the lab for PCR testing to validate the result and trigger test and trace.
NEGATIVE
NEGATIVE
Leaders of Innovation
Sheba Medical Center at Tel HaShomer is the largest and most comprehensive medical centre in the Middle East. At the forefront of medical treatments, patient care, research, innovation, and education, Sheba provides the medical and clinical data required for the research and AI analysis. Sheba has an innovation center that is dedicated to finding and
developing new medical technologies
In 2019 & 2020 Newsweek magazine named Sheba one of the top 10 hospitals in the world.
NewSight Imaging develops advanced CMOS Image sensor chips for 3D machine vision and spectral analysis, which when backed by AI, offers a unique and affordable solution for remote health, real time diagnosis and quality inspection solutions for Water, Food & Beverage, pathogens and more.
Named “Cool Vendor” in Novel Sensors category by Gartner
Awarded 3 Grants by the Israeli Innovation Authority
Inventive Health have partnered with recognised leaders of innovation to bring the SpectraLIT™ solution
Virusight Diagnostic, a joint venture between two of Israel’s leading Technology and Healthcare innovators
Internet enabled to provide immediate results
and point-of care virus detection.
Affordable tests, using readily available
disposable cuvettes
world and in discussion with several Australian
state health departments.
Independent clinical trial of nasal swab tests determined Relative sensitivity 93% and Overall accuracy > 88%
CE approved with other regulatory approvals in
progress
93%
SpectraLIT™ Delivers Results At the Speed of Light Combining the power of Mass Spectrometry and AI with Machine Learning to create substance detection and classification
Generate vectors of 1024 values each represents a
wavelength between 400 to 700nm and is expected to reach up to 1100nm soon
Exportable data is used by the AI engine to create classification
Acquires thousands of spectra profiles and generates
absorbance results within one second
Based on the NSP2020
Spectrometer Chip
Three of Inventive Health's principal executives have extensive experience and a proven track record in the eHealthcare sector across Asia Pacific, EMEA and the Americas.
Each held similar positions in iSOFT, a world leader in advanced Healthcare solutions, who oversaw its growth to over 5,000 employees and major research and development centres in UK, Central Europe, India, Australia and New Zealand.
iSOFT's solutions were deployed by over 13,000 healthcare providers including 8,000 hospitals and clinics across 40 countries and was acquired in 2011 by Computer Sciences Corporation (CSC) for in excess of $400m.
Inventive Health Executive Team Broad range of experience in building and growing eHealth businesses
Gary is the Executive Chairman of Inventive Health. He also holds the same position for Invigor Group - a data analytics and insights solution provider and is Principal of Marcel Equity - a strategic corporate advisory group.
Prior to this, Gary was CEO of iSOFT, which started in 1996 with 10 people and grew to be one of the world's leading providers of Healthcare solutions. During his tenure, Gary gained in-depth knowledge of the Healthcare sector and built relationships across all levels of government - both political and departmental.
Previously, as a qualified lawyer and corporate financier, Gary was a leading legal practitioner who practiced in the fields of corporate, securities and taxation as well as investment banking at a domestic and international level.
As a result of his diverse experience, Gary has built deep relationships with leaders within healthcare as well as the business sector including the legal, accounting and financial communities, in United Kingdom, Netherlands, Germany, Spain, ME, North and Latin America, India, China, South East Asia and Australia and New Zealand.
Gary Cohen CEO
Adrian Stevens Chief Operating Officer
Based in the UK, Adrian is currently CEO of Cambio Healthcare Systems Ltd – a Swedish healthcare provider of EPR and innovative healthcare IT software and solutions.
Adrian is a qualified clinical radiographer and holds an MBA from Durham University. He has held a variety of NHS management positions and senior sales and marketing roles in the healthcare industry, including leading the UK & European healthcare operations for 3M, Agfa and was Managing Director NEMEA for iSOFT, subsequently CSC, then the UK’s largest provider of healthcare IT.
In 2012, Adrian established Aura Healthcare to offer direction and help accelerate healthcare IT agendas across the UK, Ireland and international healthcare markets and launching its own IP in the Patient Flow sector. In May 2015 Servelec Group PLC acquired Aura Healthcare. In late 2014 he formed ADST Limited offering consultancy services to selected clients in the healthcare space including Telstra Health Australia (CloudMed) and Cambio Sweden.
Adrian’s experience makes him ideally placed to understand the risks and opportunities currently facing the healthcare sector. His strong industry experience enables him to guide and support executive leadership teams within healthcare to adapt and succeed within the current global climate arising from the recent pandemic.
Dr David Dembo Chief Medical Officer
David is a medical doctor with over 30 years of health technology experience, having held a range of senior roles at Merck Sharp & Dohme, IBM, Microsoft, GE and Orion.
David is passionate about medical technology and the use of data to improve quality and safety and has a specific passion for AI and Analytics. He has combined his understanding of medicine and business to assist technology companies to grow their businesses across Asia Pacific and the Middle East and improve the quality and accessibility of healthcare solutions.
In David’s role as Chief Medical Officer for Inventive Health, he works closely with customers, regulators, and the commercial teams to ensure and enable the safe and seamless adoption of the company’s technologies.
David’s qualifications span medicine, health economics, e-commerce, business, international management and AI.
Gregory brings to Inventive Health his significant expertise in the Financial Services sector and operational market experience in Australia, Europe, SouthEast Asia, India, and China which he gained from a 27 year career with Ford Motor Credit Company Limited, the captive financing arm of Ford Motor Company.
With a proven track record of success in leading teams to deliver superior results, Gregory has global market expertise in sales, marketing and distribution predominantly in the Automotive industry.
Greg has experience in building strong relationships with OEM suppliers, auto dealers, industry councils and Governments to achieve profitable long-term partnerships and maximize market opportunities.
Gregory Cohen Chief Financial Officer
Merger of Inventive Health with Virusight Combining Inventive Health’s expertise in building
successful businesses with the visionary technology and science of Virusight to create a global healthcare company providing the rapid and cost- effective Point of Care testing for all pathogens including SARS-CoV-2.
Create world class solutions that continue to improve and inspire the market.
Create health data that will be highly valued.
Create a leading global market brand.
NewSight
INVENTIVE HEALTHCARE SOLUTIONS REVISED CORPORATE STRUCTURE
Board
Revenue 26,874 188,552 224,876 440,301
Cost of Goods Sold -5,265 -51,182 -61,179 -117,626 Direct Operating Costs -5,571 -18,774 -19,981 -44,326 Total COGS and Operating Costs -10,837 -69,956 -81,160 -161,953
Gross Margin 16,037 118,596 143,716 278,349
Regional Office Indirect Costs -777 -1,779 -1,779 -4,335 Corporate Indirect Costs -3,265 -8,184 -9,011 -20,460 Total Indirect Costs -4,043 -9,962 -10,790 -24,795
EBITDA 11,994 108,633 132,926 253,554
Other Expenses -1,199 -10,863 -13,293 -25,355 NPAT 10,795 97,770 119,633 228,198
All Regions
Reconciliation
Reconciliation
Period
Jul-21
Aug-21
Sep-21
Oct-21
Nov-21
Dec-21
Jan-22
Feb-22
Mar-22
Apr-22
May-22
Jun-22
Jul-22
Aug-22
Sep-22
Oct-22
Nov-22
Dec-22
Jan-23
Feb-23
Mar-23
Apr-23
May-23
Jun-23
Jul-23
Aug-23
Sep-23
Oct-23
Nov-23
Dec-23
Actual/Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Data
(998,138)
70,508
1,478,262
1,324,929
3,229,983
3,206,641
5,170,481
6,353,434
6,367,241
6,375,364
6,375,364
6,375,364
6,385,114
6,376,114
6,376,114
6,376,114
6,376,114
6,376,114
6,873,336
7,737,807
7,761,918
7,761,644
7,761,644
7,761,644
7,749,737
7,749,737
7,749,737
7,736,838
7,736,838
7,736,838
Fx rate
2021
2022
2023
Total
-8344202.88
-53866113.24
-62493319.01
-124703635.1
-10836627.12
-69955991.22
-81160154.56
-161952772.9
2021
2022
2023
Total
???
5823564.472
73449199.2
91284786.96
170557550.6
7563070.743
95388570.39
118551671.4
221503312.5
???
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
???
5000000
0
0
5000000
6493506.494
0
0
6493506.494
5000000
0
0
5000000
6493506.494
0
0
6493506.494
10823564.47
73449199.2
91284786.96
175557550.6
14056577.24
95388570.39
118551671.4
227996819
10823564.47
84272763.67
175557550.6
175557550.6
14056577.24
109445147.6
227996819
227996819
4.0 x
19.9 x
37.6 x
4.0 x
19.9 x
37.6 x
2021
2022
2023
Total
Seg1
Seg2
2991024
12453520
12358320
27802864
-4054333.2
-39410200.4
-47107824.4
-90572358
-124166.6667
-377100
-395955
-897221.6667
-8344202.88
-53866113.24
-62493319.01
-124703635.1
-275000
-630000
-661500
-1566500
-598540
-1369643
-1369875.15
-3338058.15
-1659371.542
-4307441.64
-4844454.912
-10811268.09
-20000
-240500
-252525
-513025
???
19869319.18
167006396.5
202073976.7
388949692.4
6747140.63
81813969.81
101520088.9
190081199.3
???
Cash flows from financing activities
???
2000000
0
0
2000000
0
0
0
0
0
0
0
0
2000000
0
0
2000000
Cash at beginning
6747140.63
81813969.81
101520088.9
0
0
0
2000000
0
0
8747140.63
90561110.44
192081199.3
0
169,100
459,902
459,902
951,060
951,060
1,125,060
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
2,991,024
12,453,520
12,358,320
27,802,864
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-8,333
-20,167
-20,167
-25,167
-25,167
-25,167
-31,425
-31,425
-31,425
-31,425
-31,425
-31,425
-31,425
-31,425
-31,425
-31,425
-31,425
-31,425
-32,996
-32,996
-32,996
-32,996
-32,996
-32,996
-32,996
-32,996
-32,996
-32,996
-32,996
-32,996
-124,167
-377,100
-395,955
-897,222
-713,375
-737,050
-1,170,265
-1,265,265
-2,212,124
-2,246,124
-4,266,522
-4,501,236
-4,501,236
-4,505,236
-4,505,236
-4,505,236
-4,505,236
-4,515,236
-4,515,236
-4,515,236
-4,515,236
-4,515,236
-4,919,223
-5,219,275
-5,219,275
-5,223,685
-5,223,685
-5,223,685
-5,236,915
-5,236,915
-5,236,915
-5,251,248
-5,251,248
-5,251,248
-8,344,203
-53,866,113
-62,493,319
-124,703,635
-25,000
-50,000
-50,000
-50,000
-50,000
-50,000
-52,500
-52,500
-52,500
-52,500
-52,500
-52,500
-52,500
-52,500
-52,500
-52,500
-52,500
-52,500
-55,125
-55,125
-55,125
-55,125
-55,125
-55,125
-55,125
-55,125
-55,125
-55,125
-55,125
-55,125
-275,000
-630,000
-661,500
-1,566,500
-47,917
-97,625
-97,625
-118,458
-118,458
-118,458
-119,554
-119,554
-119,554
-119,554
-119,554
-119,554
-108,720
-108,720
-108,720
-108,720
-108,720
-108,720
-114,156
-114,156
-114,156
-114,156
-114,156
-114,156
-114,156
-114,156
-114,156
-114,156
-114,156
-114,156
-598,540
-1,369,643
-1,369,875
-3,338,058
-205,250
-205,250
-255,470
-310,007
-345,730
-337,665
-367,792
-382,754
-367,413
-354,387
-354,387
-354,387
-354,387
-354,387
-354,387
-354,387
-354,387
-354,387
-405,025
-431,299
-404,508
-400,403
-400,403
-400,403
-400,403
-400,403
-400,403
-400,403
-400,403
-400,403
-1,659,372
-4,307,442
-4,844,455
-10,811,268
-3,333
-3,333
-3,333
-3,333
-3,333
-3,333
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-20,000
-240,500
-252,525
-513,025
-17,708
-35,417
-35,417
-35,417
-35,417
-35,417
-37,188
-37,188
-37,188
-37,188
-37,188
-37,188
-37,188
-37,188
-37,188
-37,188
-37,188
-37,188
-39,047
-39,047
-39,047
-39,047
-39,047
-39,047
-39,047
-39,047
-39,047
-39,047
-39,047
-39,047
-194,792
-446,250
-468,563
-1,109,604
-205,250
-205,250
-205,250
-222,250
-222,250
-222,250
-233,363
-233,363
-233,363
-233,363
-233,363
-233,363
-233,363
-233,363
-233,363
-233,363
-233,363
-233,363
-245,031
-245,031
-245,031
-245,031
-245,031
-245,031
-245,031
-245,031
-245,031
-245,031
-245,031
-245,031
-1,282,500
-2,800,350
-2,940,368
-7,023,218
-3,333
-3,333
-3,333
-3,333
-3,333
-3,333
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-20,000
-240,500
-252,525
-513,025
0
0
32,802
32,802
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
159,324
562,320
562,320
1,283,964
002
1002
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
002
3103
0
-11,833
-11,833
-11,833
-11,833
-11,833
-12,425
-12,425
-12,425
-12,425
-12,425
-12,425
-12,425
-12,425
-12,425
-12,425
-12,425
-12,425
-13,046
-13,046
-13,046
-13,046
-13,046
-13,046
-13,046
-13,046
-13,046
-13,046
-13,046
-13,046
-59,167
-149,100
-156,555
-364,822
002
3106
Marketing
0
-23,667
-23,667
-23,667
-23,667
-23,667
-24,850
-24,850
-24,850
-24,850
-24,850
-24,850
-24,850
-24,850
-24,850
-24,850
-24,850
-24,850
-26,093
-26,093
-26,093
-26,093
-26,093
-26,093
-26,093
-26,093
-26,093
-26,093
-26,093
-26,093
-118,333
-298,200
-313,110
-729,643
002
3107
Distribution
0
-3,254
-3,254
-3,254
-3,254
-3,254
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-16,271
-41,003
-43,053
-100,326
002
3108
Insurance
0
-3,254
-3,254
-3,254
-3,254
-3,254
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-16,271
-41,003
-43,053
-100,326
002
3001
0
-137,977
-177,364
-177,364
-228,061
-228,061
-225,385
-225,385
-225,385
-225,385
-225,385
-225,385
-225,385
-225,385
-225,385
-225,385
-225,385
-225,385
-230,169
-257,364
-257,364
-257,364
-257,364
-257,364
-257,364
-257,364
-257,364
-257,364
-257,364
-257,364
-948,827
-2,704,622
-3,061,177
-6,714,627
0
-25,000
-25,000
-25,000
-25,000
-25,000
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-125,000
-315,000
-330,750
-770,750
002
4005
0
0
0
0
0
0
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
0
2,088,000
2,088,000
4,176,000
003
1002
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
003
3103
0
0
0
0
0
0
-5,000
-5,000
-5,000
-5,000
-5,000
-5,000
-5,000
-5,000
-5,000
-5,000
-5,000
-5,000
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
0
-60,000
-63,000
-123,000
003
3106
Marketing
0
0
0
0
0
0
-6,667
-6,667
-6,667
-6,667
-6,667
-6,667
-6,667
-6,667
-6,667
-6,667
-6,667
-6,667
-7,000
-7,000
-7,000
-7,000
-7,000
-7,000
-7,000
-7,000
-7,000
-7,000
-7,000
-7,000
0
-80,000
-84,000
-164,000
003
3107
Distribution
0
0
0
0
0
0
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
0
-50,000
-52,500
-102,500
003
3108
Insurance
0
0
0
0
0
0
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
0
-50,000
-52,500
-102,500
003
3001
0
0
0
0
0
0
-2,057,469
-2,037,469
-2,037,469
-2,037,469
-2,037,469
-2,037,469
-2,037,469
-2,037,469
-2,037,469
-2,037,469
-2,037,469
-2,037,469
-2,455,002
-2,455,002
-2,455,002
-2,455,002
-2,455,002
-2,455,002
-2,455,002
-2,455,002
-2,455,002
-2,455,002
-2,455,002
-2,455,002
0
-24,469,627
-29,460,023
-53,929,650
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
003
4005
0
0
0
0
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
498,000
2,988,000
2,988,000
6,474,000
004
1002
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
004
3103
0
0
0
-5,000
-5,000
-5,000
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
-5,513
-5,513
-5,513
-5,513
-5,513
-5,513
-5,513
-5,513
-5,513
-5,513
-5,513
-5,513
-15,000
-63,000
-66,150
-144,150
004
3106
Marketing
0
0
0
-1,667
-1,667
-1,667
-1,750
-1,750
-1,750
-1,750
-1,750
-1,750
-1,750
-1,750
-1,750
-1,750
-1,750
-1,750
-1,838
-1,838
-1,838
-1,838
-1,838
-1,838
-1,838
-1,838
-1,838
-1,838
-1,838
-1,838
-5,000
-21,000
-22,050
-48,050
004
3107
Distribution
0
0
0
-4,167
-4,167
-4,167
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-12,500
-52,500
-55,125
-120,125
004
3108
Insurance
0
0
0
-4,167
-4,167
-4,167
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-12,500
-52,500
-55,125
-120,125
004
3001
0
0
0
-25,000
-599,450
-599,450
-559,897
-826,564
-826,564
-826,564
-826,564
-826,564
-826,564
-826,564
-826,564
-826,564
-826,564
-826,564
-781,438
-1,031,437
-1,031,437
-1,031,437
-1,031,437
-1,031,437
-1,031,437
-1,031,437
-1,031,437
-1,031,437
-1,031,437
-1,031,437
-1,223,900
-9,652,099
-12,127,245
-23,003,244
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
004
4005
0
169,100
427,100
427,100
655,200
655,200
655,200
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
2,333,700
6,815,200
6,720,000
15,868,900
005
1002
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
005
3103
-8,333
-8,333
-8,333
-8,333
-8,333
-8,333
-8,750
-8,750
-8,750
-8,750
-8,750
-8,750
-8,750
-8,750
-8,750
-8,750
-8,750
-8,750
-9,188
-9,188
-9,188
-9,188
-9,188
-9,188
-9,188
-9,188
-9,188
-9,188
-9,188
-9,188
-50,000
-105,000
-110,250
-265,250
005
3106
Marketing
-12,500
-12,500
-12,500
-12,500
-12,500
-12,500
-13,125
-13,125
-13,125
-13,125
-13,125
-13,125
-13,125
-13,125
-13,125
-13,125
-13,125
-13,125
-13,781
-13,781
-13,781
-13,781
-13,781
-13,781
-13,781
-13,781
-13,781
-13,781
-13,781
-13,781
-75,000
-157,500
-165,375
-397,875
005
3107
Distribution
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-25,000
-52,500
-55,125
-132,625
005
3108
Insurance
-25,000
-25,000
-25,000
-25,000
-25,000
-25,000
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-150,000
-315,000
-330,750
-795,750
005
3001
-695,667
-563,656
-957,484
-1,027,484
-1,349,197
-1,383,197
-1,386,584
-1,374,630
-1,374,630
-1,378,630
-1,378,630
-1,378,630
-1,378,630
-1,388,630
-1,388,630
-1,388,630
-1,388,630
-1,388,630
-1,413,568
-1,436,425
-1,436,425
-1,440,835
-1,440,835
-1,440,835
-1,454,065
-1,454,065
-1,454,065
-1,468,398
-1,468,398
-1,468,398
-5,976,684
-16,593,514
-17,376,312
-39,946,510
-25,000
-25,000
-25,000
-25,000
-25,000
-25,000
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-150,000
-315,000
-330,750
-795,750
005
4005
???
0
638,625
2,639,034
3,635,734
5,553,636
7,402,291
9,809,931
13,444,581
14,450,968
14,419,985
14,369,862
14,358,724
14,358,724
14,358,724
14,358,724
14,358,724
14,358,724
14,358,724
14,920,185
16,377,275
17,077,652
17,077,652
17,077,652
17,077,652
17,077,652
17,077,652
17,077,652
17,077,652
17,077,652
17,077,652
19,869,319
167,006,396
202,073,977
388,949,692
-822,916
-527,176
573,646
1,286,554
1,457,516
3,855,940
2,047,791
5,529,181
7,678,825
6,215,200
6,186,827
7,581,678
4,649,663
6,176,439
7,582,428
6,042,300
6,176,439
7,582,428
4,658,730
6,982,776
9,055,854
7,537,224
7,578,627
9,051,475
5,811,946
7,566,720
9,039,568
7,421,377
7,553,821
9,026,669
5,823,564
73,449,199
91,284,787
170,557,551
???
0
???
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Cash at beginning
-822,916
-527,176
573,646
1,286,554
1,457,516
3,855,940
2,047,791
5,529,181
7,678,825
6,215,200
6,186,827
7,581,678
4,649,663
6,176,439
7,582,428
6,042,300
6,176,439
7,582,428
4,658,730
6,982,776
9,055,854
7,537,224
7,578,627
9,051,475
5,811,946
7,566,720
9,039,568
7,421,377
7,553,821
9,026,669
5,823,564
73,449,199
91,284,787
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,177,084
3,649,908
4,223,554
5,510,108
6,967,624
10,823,564
12,871,356
18,400,536
26,079,361
32,294,561
38,481,388
46,063,067
50,712,730
56,889,169
64,471,597
70,513,897
76,690,336
84,272,764
88,931,494
95,914,270
104,970,124
112,507,348
120,085,975
129,137,450
134,949,396
142,516,116
151,555,684
158,977,061
166,530,882
175,557,551
10,823,564
84,272,764
175,557,551
001
9001
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
001
9002
-222,088
-251,517
-251,517
-261,817
-261,817
-261,817
-856,667
-289,795
-289,795
-289,795
-289,795
-289,795
-909,295
-289,795
-289,795
-289,795
-289,795
-289,795
-922,704
-304,285
-304,285
-304,285
-304,285
-304,285
-954,760
-304,285
-304,285
-304,285
-304,285
-304,285
-1,510,571
-4,663,912
-4,920,311
-11,094,794
001
5203
investments
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
001
9007
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
001
9008
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
001
9009
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
001
9010
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Cash at beginning
-222,088
-251,517
-251,517
-261,817
-261,817
-261,817
-856,667
-289,795
-289,795
-289,795
-289,795
-289,795
-909,295
-289,795
-289,795
-289,795
-289,795
-289,795
-922,704
-304,285
-304,285
-304,285
-304,285
-304,285
-954,760
-304,285
-304,285
-304,285
-304,285
-304,285
-1,510,571
-4,663,912
-4,920,311
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,777,913
1,526,396
1,274,879
1,013,063
751,246
489,429
-367,238
-657,033
-946,828
-1,236,623
-1,526,418
-1,816,213
-2,725,508
-3,015,303
-3,305,098
-3,594,893
-3,884,688
-4,174,483
-5,097,186
-5,401,471
-5,705,756
-6,010,041
-6,314,325
-6,618,610
-7,573,370
-7,877,655
-8,181,939
-8,486,224
-8,790,509
-9,094,794
489,429
-4,174,483
-9,094,794
002
9001
0
0
704,391
954,666
1,127,869
1,301,072
1,312,600
1,603,311
1,604,998
1,604,998
1,604,998
1,604,998
1,604,998
1,604,998
1,604,998
1,604,998
1,604,998
1,604,998
1,604,998
1,901,698
2,003,146
2,003,146
2,003,146
2,003,146
2,003,146
2,003,146
2,003,146
2,003,146
2,003,146
2,003,146
4,087,998
18,965,886
23,538,153
46,592,037
002
9002
0
-150,867
146,395
364,319
440,300
607,596
189,144
766,012
754,015
709,324
752,712
752,712
-71,620
752,712
752,712
709,324
752,712
752,712
-18,512
878,363
966,024
915,462
965,613
965,613
-59,775
965,613
965,613
912,081
965,613
965,613
1,407,744
7,572,472
9,387,324
18,367,540
002
5203
investments
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
002
9007
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
002
9008
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
002
9009
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
002
9010
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Cash at beginning
0
-150,867
146,395
364,319
440,300
607,596
189,144
766,012
754,015
709,324
752,712
752,712
-71,620
752,712
752,712
709,324
752,712
752,712
-18,512
878,363
966,024
915,462
965,613
965,613
-59,775
965,613
965,613
912,081
965,613
965,613
1,407,744
7,572,472
9,387,324
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-150,867
-4,472
359,848
800,147
1,407,744
1,596,888
2,362,900
3,116,915
3,826,239
4,578,951
5,331,663
5,260,043
6,012,755
6,765,467
7,474,791
8,227,503
8,980,216
8,961,704
9,840,067
10,806,091
11,721,553
12,687,167
13,652,780
13,593,005
14,558,619
15,524,232
16,436,313
17,401,926
18,367,540
1,407,744
8,980,216
18,367,540
003
9001
0
0
0
0
0
0
2,245,832
4,577,794
4,663,924
4,683,064
4,683,064
4,683,064
4,683,064
4,683,064
4,683,064
4,683,064
4,683,064
4,683,064
5,244,525
5,805,986
5,805,986
5,805,986
5,805,986
5,805,986
5,805,986
5,805,986
5,805,986
5,805,986
5,805,986
5,805,986
0
53,635,127
69,110,370
122,745,497
003
9002
0
0
0
0
0
0
-137,951
1,997,126
2,085,456
1,721,436
2,104,596
2,104,596
1,729,994
2,114,346
2,114,346
1,731,186
2,114,346
2,114,346
1,738,307
2,634,601
2,634,601
2,317,911
2,634,601
2,634,601
2,317,911
2,634,601
2,634,601
2,317,911
2,634,601
2,634,601
0
21,793,821
29,768,851
51,562,673
003
5203
investments
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
003
9007
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
003
9008
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
003
9009
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
003
9010
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Cash at beginning
0
0
0
0
0
0
-137,951
1,997,126
2,085,456
1,721,436
2,104,596
2,104,596
1,729,994
2,114,346
2,114,346
1,731,186
2,114,346
2,114,346
1,738,307
2,634,601
2,634,601
2,317,911
2,634,601
2,634,601
2,317,911
2,634,601
2,634,601
2,317,911
2,634,601
2,634,601
0
21,793,821
29,768,851
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-137,951
1,859,174
3,944,630
5,666,066
7,770,662
9,875,258
11,605,252
13,719,598
15,833,944
17,565,130
19,679,476
21,793,821
23,532,129
26,166,730
28,801,331
31,119,243
33,753,844
36,388,445
38,706,356
41,340,958
43,975,559
46,293,470
48,928,071
51,562,673
0
21,793,821
51,562,673
004
9001
0
0
0
0
876,915
1,753,830
1,753,830
2,241,331
2,728,832
2,728,832
2,728,832
2,728,832
2,728,832
2,728,832
2,728,832
2,728,832
2,728,832
2,728,832
2,728,832
3,216,330
3,703,828
3,703,828
3,703,828
3,703,828
3,703,828
3,703,828
3,703,828
3,703,828
3,703,828
3,703,828
2,630,745
31,283,480
42,983,442
76,897,668
004
9002
0
0
0
-37,058
179,683
1,015,695
570,085
1,163,136
1,631,137
891,496
1,631,137
1,631,137
791,496
1,631,137
1,631,137
791,496
1,631,137
1,631,137
785,408
1,765,239
2,233,237
1,366,871
2,233,237
2,233,237
1,283,538
2,233,237
2,233,237
1,283,538
2,233,237
2,233,237
1,158,321
15,625,667
22,117,255
38,901,242
004
5203
investments
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
004
9007
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
004
9008
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
004
9009
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
004
9010
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Cash at beginning
0
0
0
-37,058
179,683
1,015,695
570,085
1,163,136
1,631,137
891,496
1,631,137
1,631,137
791,496
1,631,137
1,631,137
791,496
1,631,137
1,631,137
785,408
1,765,239
2,233,237
1,366,871
2,233,237
2,233,237
1,283,538
2,233,237
2,233,237
1,283,538
2,233,237
2,233,237
1,158,321
15,625,667
22,117,255
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-37,058
142,626
1,158,321
1,728,406
2,891,542
4,522,678
5,414,175
7,045,311
8,676,448
9,467,944
11,099,081
12,730,218
13,521,714
15,152,850
16,783,987
17,569,395
19,334,634
21,567,872
22,934,742
25,167,980
27,401,217
28,684,755
30,917,992
33,151,230
34,434,767
36,668,005
38,901,242
1,158,321
16,783,987
38,901,242
005
9001
0
638,625
1,934,643
2,681,068
3,548,852
4,347,389
4,497,670
5,022,145
5,453,214
5,403,092
5,352,969
5,341,830
5,341,830
5,341,830
5,341,830
5,341,830
5,341,830
5,341,830
5,341,830
5,453,261
5,564,692
5,564,692
5,564,692
5,564,692
5,564,692
5,564,692
5,564,692
5,564,692
5,564,692
5,564,692
13,150,576
63,121,902
66,442,011
142,714,490
005
9002
-600,829
-124,792
678,767
1,221,109
1,099,350
2,494,465
2,283,180
1,892,702
3,498,012
3,182,739
1,988,178
3,383,028
3,109,088
1,968,039
3,374,028
3,100,088
1,968,039
3,374,028
3,076,231
2,008,857
3,526,277
3,241,264
2,049,460
3,522,308
3,225,032
2,037,553
3,510,401
3,212,132
2,024,654
3,497,501
4,768,071
33,121,151
34,931,668
72,820,890
005
5203
investments
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
005
9007
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
005
9008
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
005
9009
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
005
9010
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Cash at beginning
-600,829
-124,792
678,767
1,221,109
1,099,350
2,494,465
2,283,180
1,892,702
3,498,012
3,182,739
1,988,178
3,383,028
3,109,088
1,968,039
3,374,028
3,100,088
1,968,039
3,374,028
3,076,231
2,008,857
3,526,277
3,241,264
2,049,460
3,522,308
3,225,032
2,037,553
3,510,401
3,212,132
2,024,654
3,497,501
4,768,071
33,121,151
34,931,668
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-600,829
-725,621
-46,853
1,174,256
2,273,605
4,768,071
7,051,251
8,943,953
12,441,965
15,624,704
17,612,882
20,995,910
24,104,998
26,073,038
29,447,066
32,547,154
34,515,194
37,889,222
40,965,453
42,974,309
46,500,586
49,741,850
51,791,310
55,313,617
58,538,649
60,576,202
64,086,603
67,298,735
69,323,389
72,820,890
4,768,071
37,889,222
72,820,890
Suspects Under Consideration/of Interest
CY2021 (Jul-Dec 21)
CY2021 (Jul-Dec 21)
CY2021 (Jul-Dec 21)
$1,200
$1.0
1,000
1,000
1,000
3,500,000
8,500,000
Jessie Gu: Jessie Gu: 6m in first 6mth, then 4m in second 6 mnth
8,500,000
$4,700,000
$9,700,000
$9,700,000
95%
$4,465,000
$9,215,000
$9,215,000
Spain
Suspects Under Consideration/of Interest
Suspects Under Consideration/of Interest
Suspects Under Consideration/of Interest
CY2021 (Jul-Dec 21)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
001
9008
CF
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
001
9009
CF
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
001
9010
CF
0
0
32,802
32,802
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
159,324
562,320
562,320
002
1002
PL
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
002
3103
PL
0
-11,833
-11,833
-11,833
-11,833
-11,833
-12,425
-12,425
-12,425
-12,425
-12,425
-12,425
-12,425
-12,425
-12,425
-12,425
-12,425
-12,425
-13,046
-13,046
-13,046
-13,046
-13,046
-13,046
-13,046
-13,046
-13,046
-13,046
-13,046
-13,046
-59,167
-149,100
-156,555
002
3106
PL
Marketing
0
-23,667
-23,667
-23,667
-23,667
-23,667
-24,850
-24,850
-24,850
-24,850
-24,850
-24,850
-24,850
-24,850
-24,850
-24,850
-24,850
-24,850
-26,093
-26,093
-26,093
-26,093
-26,093
-26,093
-26,093
-26,093
-26,093
-26,093
-26,093
-26,093
-118,333
-298,200
-313,110
002
3107
PL
Distribution
0
-3,254
-3,254
-3,254
-3,254
-3,254
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-16,271
-41,003
-43,053
002
3108
PL
Insurance
0
-3,254
-3,254
-3,254
-3,254
-3,254
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,417
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-3,588
-16,271
-41,003
-43,053
002
3001
PL
0
-25,000
-25,000
-25,000
-25,000
-25,000
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-125,000
-315,000
-330,750
002
4005
PL
0
0
704,391
954,666
1,127,869
1,301,072
1,312,600
1,603,311
1,604,998
1,604,998
1,604,998
1,604,998
1,604,998
1,604,998
1,604,998
1,604,998
1,604,998
1,604,998
1,604,998
1,901,698
2,003,146
2,003,146
2,003,146
2,003,146
2,003,146
2,003,146
2,003,146
2,003,146
2,003,146
2,003,146
4,087,998
18,965,886
23,538,153
002
9002
CF
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
002
9008
CF
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
002
9009
CF
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
002
9010
CF
0
0
0
0
0
0
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
174,000
0
2,088,000
2,088,000
003
1002
PL
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
003
3103
PL
0
0
0
0
0
0
-5,000
-5,000
-5,000
-5,000
-5,000
-5,000
-5,000
-5,000
-5,000
-5,000
-5,000
-5,000
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
0
-60,000
-63,000
003
3106
PL
Marketing
0
0
0
0
0
0
-6,667
-6,667
-6,667
-6,667
-6,667
-6,667
-6,667
-6,667
-6,667
-6,667
-6,667
-6,667
-7,000
-7,000
-7,000
-7,000
-7,000
-7,000
-7,000
-7,000
-7,000
-7,000
-7,000
-7,000
0
-80,000
-84,000
003
3107
PL
Distribution
0
0
0
0
0
0
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
0
-50,000
-52,500
003
3108
PL
Insurance
0
0
0
0
0
0
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
0
-50,000
-52,500
003
3001
PL
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
003
4005
PL
0
0
0
0
0
0
2,245,832
4,577,794
4,663,924
4,683,064
4,683,064
4,683,064
4,683,064
4,683,064
4,683,064
4,683,064
4,683,064
4,683,064
5,244,525
5,805,986
5,805,986
5,805,986
5,805,986
5,805,986
5,805,986
5,805,986
5,805,986
5,805,986
5,805,986
5,805,986
0
53,635,127
69,110,370
003
9002
CF
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
003
9008
CF
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
003
9009
CF
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
003
9010
CF
0
0
0
0
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
249,000
498,000
2,988,000
2,988,000
004
1002
PL
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
004
3103
PL
0
0
0
-5,000
-5,000
-5,000
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
-5,250
-5,513
-5,513
-5,513
-5,513
-5,513
-5,513
-5,513
-5,513
-5,513
-5,513
-5,513
-5,513
-15,000
-63,000
-66,150
004
3106
PL
Marketing
0
0
0
-1,667
-1,667
-1,667
-1,750
-1,750
-1,750
-1,750
-1,750
-1,750
-1,750
-1,750
-1,750
-1,750
-1,750
-1,750
-1,838
-1,838
-1,838
-1,838
-1,838
-1,838
-1,838
-1,838
-1,838
-1,838
-1,838
-1,838
-5,000
-21,000
-22,050
004
3107
PL
Distribution
0
0
0
-4,167
-4,167
-4,167
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-12,500
-52,500
-55,125
004
3108
PL
Insurance
0
0
0
-4,167
-4,167
-4,167
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-12,500
-52,500
-55,125
004
3001
PL
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
004
4005
PL
0
0
0
0
876,915
1,753,830
1,753,830
2,241,331
2,728,832
2,728,832
2,728,832
2,728,832
2,728,832
2,728,832
2,728,832
2,728,832
2,728,832
2,728,832
2,728,832
3,216,330
3,703,828
3,703,828
3,703,828
3,703,828
3,703,828
3,703,828
3,703,828
3,703,828
3,703,828
3,703,828
2,630,745
31,283,480
42,983,442
004
9002
CF
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
004
9008
CF
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
004
9009
CF
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
004
9010
CF
0
169,100
427,100
427,100
655,200
655,200
655,200
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
560,000
2,333,700
6,815,200
6,720,000
005
1002
PL
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
005
3103
PL
-8,333
-8,333
-8,333
-8,333
-8,333
-8,333
-8,750
-8,750
-8,750
-8,750
-8,750
-8,750
-8,750
-8,750
-8,750
-8,750
-8,750
-8,750
-9,188
-9,188
-9,188
-9,188
-9,188
-9,188
-9,188
-9,188
-9,188
-9,188
-9,188
-9,188
-50,000
-105,000
-110,250
005
3106
PL
Marketing
-12,500
-12,500
-12,500
-12,500
-12,500
-12,500
-13,125
-13,125
-13,125
-13,125
-13,125
-13,125
-13,125
-13,125
-13,125
-13,125
-13,125
-13,125
-13,781
-13,781
-13,781
-13,781
-13,781
-13,781
-13,781
-13,781
-13,781
-13,781
-13,781
-13,781
-75,000
-157,500
-165,375
005
3107
PL
Distribution
-4,167
-4,167
-4,167
-4,167
-4,167
-4,167
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,375
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-4,594
-25,000
-52,500
-55,125
005
3108
PL
Insurance
-25,000
-25,000
-25,000
-25,000
-25,000
-25,000
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-150,000
-315,000
-330,750
005
3001
PL
-25,000
-25,000
-25,000
-25,000
-25,000
-25,000
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-26,250
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-27,563
-150,000
-315,000
-330,750
005
4005
PL
0
638,625
1,934,643
2,681,068
3,548,852
4,347,389
4,497,670
5,022,145
5,453,214
5,403,092
5,352,969
5,341,830
5,341,830
5,341,830
5,341,830
5,341,830
5,341,830
5,341,830
5,341,830
5,453,261
5,564,692
5,564,692
5,564,692
5,564,692
5,564,692
5,564,692
5,564,692
5,564,692
5,564,692
5,564,692
13,150,576
63,121,902
66,442,011
005
9002
CF
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
005
9008
CF
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
005
9009
CF
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
005
9010
CF
1001
PL
Revenue
001
Corporate
001
1002
2003
PL
COGS
3001
3105
PL
4004
PL
9001
CF
9007
CF
9008
CF
9009
CF
Virusight Financials – Cash Flow BUSINESS PLANNING SUMMARY (AUD '000)
CASH FLOW (Before intercompany eliminations) 2021 2022 2023 Total Cash flows from operating activities Receipts from customers 25,804 216,891 262,434 505,129 Supplier Payments -10,355 -71,192 -84,508 -166,055 Salaries and Wages Payment -3,594 -19,643 -22,399 -45,635 GST/VAT (paid) received -3,093 -19,805 -23,683 -46,581 Withholding Tax (paid) received -1,199 -10,863 -13,293 -25,355 Net cash from / (used in) operating activities 7,563 95,389 118,552 221,503
Cash flows from investing activities Payments to acquire or for Investments 0 0 0 0 Net cash from / (used in) investing activities 0 0 0 0
Cash flows from financing activities Proceeds from issues of equity securities 6,494 0 0 6,494 Capital raise costs 0 0 0 0 Net cash from / (used in) financing activities 6,494 0 0 6,494
Net increase (decrease) in cash for the period 14,057 95,389 118,552 227,997 Cash at beginning 0 14,057 109,445 0
Cash at end of period 14,057 109,445 227,997 227,997
All Regions
Reconciliation
Reconciliation
Period
Jul-21
Aug-21
Sep-21
Oct-21
Nov-21
Dec-21
Jan-22
Feb-22
Mar-22
Apr-22
May-22
Jun-22
Jul-22
Aug-22
Sep-22
Oct-22
Nov-22
Dec-22
Jan-23
Feb-23
Mar-23
Apr-23
May-23
Jun-23
Jul-23
Aug-23
Sep-23
Oct-23
Nov-23
Dec-23
Actual/Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Forecast
Data
(998,138)
70,508
1,478,262
1,324,929
3,229,983
3,206,641
5,170,481
6,353,434
6,367,241
6,375,364
6,375,364
6,375,364
6,385,114
6,376,114
6,376,114
6,376,114
6,376,114
6,376,114
6,873,336
7,737,807
7,761,918
7,761,644
7,761,644
7,761,644
7,749,737
7,749,737
7,749,737
7,736,838
7,736,838
7,736,838
Fx rate
2021
2022
2023
Total
-8344202.88
-53866113.24
-62493319.01
-124703635.1
-10836627.12
-69955991.22
-81160154.56
-161952772.9
Fx rate
2021
2022
2023
Total
???
5823564.472
73449199.2
91284786.96
170557550.6
7563070.743
95388570.39
118551671.4
221503312.5
???
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
???
5000000
0
0
5000000
6493506.494
0
0
6493506.494
5000000
0
0
5000000
6493506.494
0
0
6493506.494
10823564.47
73449199.2
91284786.96
175557550.6
14056577.24
95388570.39
118551671.4
227996819
10823564.47
84272763.67
175557550.6
175557550.6
14056577.24
109445147.6
227996819
227996819
4.0 x
19.9 x
37.6 x
4.0 x
19.9 x
37.6 x
2021
2022
2023
Total
Seg1
Seg2
2991024
12453520
12358320
27802864
-4054333.2
-39410200.4
-47107824.4
-90572358
-124166.6667
-377100
-395955
-897221.6667
-8344202.88
-53866113.24
-62493319.01
-124703635.1
-275000
-630000
-661500
-1566500
-598540
-1369643
-1369875.15
-3338058.15
-1659371.542
-4307441.64
-4844454.912
-10811268.09
-20000
-240500
-252525
-513025
???
19869319.18
167006396.5
202073976.7
388949692.4
6747140.63
81813969.81
101520088.9
190081199.3
???
Cash flows from financing activities
???
2000000
0
0
2000000
0
0
0
0
0
0
0
0
2000000
0
0
2000000
Cash at beginning
6747140.63
81813969.81
101520088.9
0
0
0
2000000
0
0
8747140.63
90561110.44
192081199.3
0
169,100
459,902
459,902
951,060
951,060
1,125,060
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
1,029,860
2,991,024
12,453,520
12,358,320
27,802,864
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-8,333
-20,167
-20,167
-25,167
-25,167
-25,167
-31,425
-31,425
-31,425
-31,425
-31,425
-31,425
-31,425
-31,425
-31,425
-31,425
-31,425
-31,425
-32,996
-32,996
-32,996
-32,996
-32,996
-32,996
-32,996
-32,996
-32,996
-32,996
-32,996
-32,996
-124,167
-377,100
-395,955
-897,222
-713,375
-737,050
-1,170,265
-1,265,265
-2,212,124
-2,246,124
-4,266,522
-4,501,236
-4,501,236
-4,505,236
-4,505,236
-4,505,236
-4,505,236
-4,515,236
-4,515,236
-4,515,236
-4,515,236
-4,515,236
-4,919,223
-5,219,275
-5,219,275
-5,223,685
-5,223,685
-5,223,685
-5,236,915
-5,236,915
-5,236,915
-5,251,248
-5,251,248
-5,251,248
-8,344,203
-53,866,113
-62,493,319
-124,703,635
-25,000
-50,000
-50,000
-50,000
-50,000
-50,000
-52,500
-52,500
-52,500
-52,500
-52,500
-52,500
-52,500
-52,500
-52,500
-52,500
-52,500
-52,500
-55,125
-55,125
-55,125
-55,125
-55,125
-55,125
-55,125
-55,125
-55,125
-55,125
-55,125
-55,125
-275,000
-630,000
-661,500
-1,566,500
-47,917
-97,625
-97,625
-118,458
-118,458
-118,458
-119,554
-119,554
-119,554
-119,554
-119,554
-119,554
-108,720
-108,720
-108,720
-108,720
-108,720
-108,720
-114,156
-114,156
-114,156
-114,156
-114,156
-114,156
-114,156
-114,156
-114,156
-114,156
-114,156
-114,156
-598,540
-1,369,643
-1,369,875
-3,338,058
-205,250
-205,250
-255,470
-310,007
-345,730
-337,665
-367,792
-382,754
-367,413
-354,387
-354,387
-354,387
-354,387
-354,387
-354,387
-354,387
-354,387
-354,387
-405,025
-431,299
-404,508
-400,403
-400,403
-400,403
-400,403
-400,403
-400,403
-400,403
-400,403
-400,403
-1,659,372
-4,307,442
-4,844,455
-10,811,268
-3,333
-3,333
-3,333
-3,333
-3,333
-3,333
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-20,000
-240,500
-252,525
-513,025
-17,708
-35,417
-35,417
-35,417
-35,417
-35,417
-37,188
-37,188
-37,188
-37,188
-37,188
-37,188
-37,188
-37,188
-37,188
-37,188
-37,188
-37,188
-39,047
-39,047
-39,047
-39,047
-39,047
-39,047
-39,047
-39,047
-39,047
-39,047
-39,047
-39,047
-194,792
-446,250
-468,563
-1,109,604
-205,250
-205,250
-205,250
-222,250
-222,250
-222,250
-233,363
-233,363
-233,363
-233,363
-233,363
-233,363
-233,363
-233,363
-233,363
-233,363
-233,363
-233,363
-245,031
-245,031
-245,031
-245,031
-245,031
-245,031
-245,031
-245,031
-245,031
-245,031
-245,031
-245,031
-1,282,500
-2,800,350
-2,940,368
-7,023,218
-3,333
-3,333
-3,333
-3,333
-3,333
-3,333
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-20,042
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-21,044
-20,000
-240,500
-252,525
-513,025
0
0
32,802
32,802
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860
46,860